Shareholders Have Faith in Loss-making BioCryst Pharmaceuticals (NASDAQ:BCRX) as Stock Climbs 4.1% in Past Week, Taking Five-year Gain to 69%
Shareholders Have Faith in Loss-making BioCryst Pharmaceuticals (NASDAQ:BCRX) as Stock Climbs 4.1% in Past Week, Taking Five-year Gain to 69%
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore, you'd generally like to see the share price rise faster than the market. But BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has fallen short of that second goal, with a share price rise of 69% over five years, which is below the market return. The last year has been disappointing, with the stock price down 8.4% in that time.
當您購買並持有股票進行長期投資時，您肯定希望它能提供正向回報。此外，您通常會希望看到股票價格比市場上漲得更快。但是BioCryst製藥公司（納斯達克：BCRX）未能達到第二個目標，在過去五年中，股票價格上漲了69％，低於市場回報率。過去一年令人失望，股票價格下跌了8.4％。
Since the stock has added US$52m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.
由於該股上週僅市值就增加了5200萬美元，讓我們看看基本表現是否在推動着長期回報。
Given that BioCryst Pharmaceuticals didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually desire strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.
考慮到BioCryst製藥公司在過去的一年中未獲利，我們將專注於營收增長，以快速了解其業務發展狀況。虧損公司的股東通常希望實現強勁的營收增長。一些公司可以推遲盈利時間以加快營收增長，但在這種情況下，希望實現良好的收入增長來彌補缺少收益的不足。在過去的五年中，BioCryst製藥公司營收每年增長51％。即使與其他營收集中的公司相比，這也是一個很好的結果。股東獲得了利潤是令人高興的，但在這段時間內獲利僅爲11％，與整個市場相比並不令人印象深刻。您可以認爲市場仍然非常懷疑，考慮到營收的增加。可能是股票之前被過度定價，但如果您正在尋找被低估的成長型股票，這些數字表明這裏可能存在機會。
For the last half decade, BioCryst Pharmaceuticals can boast revenue growth at a rate of 51% per year. Even measured against other revenue-focussed companies, that's a good result. It's nice to see shareholders have made a profit, but the gain of 11% over the period isn't that impressive compared to the overall market. You could argue the market is still pretty skeptical, given the growing revenues. It could be that the stock was previously over-priced - but if you're looking for underappreciated growth stocks, these numbers indicate that there might be an opportunity here.
過去的半個十年，BioCryst製藥公司每年營收增長率達到51％。即使與其他重視營收的公司相比，這也是一個不錯的結果。看到股東賺取利潤是不錯的，但在該時期內獲得的11％收益並不令人印象深刻。您可以認爲市場仍然相當持懷疑態度，考慮到營收的增加。可能有股票之前定價過高，但如果您正在尋找被低估的增長型股票，這些數字表明這裏可能存在機會。2024年6月22日納斯達克BCRX公司盈利和營收增長。
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
以下圖像顯示了公司的營業收入和盈利（隨時間變化）（單擊以查看準確的數字）。
It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. If you are thinking of buying or selling BioCryst Pharmaceuticals stock, you should check out this free report showing analyst profit forecasts.
BioCryst製藥股東今年雖然虧損了8.4％，但市場本身上漲了26％。即使好股票的股票價格有時也會下跌，但我們要看到企業基本度量指標的改善才會產生興趣。長期投資者不會那麼沮喪，因爲他們在五年內每年都會獲得11％的回報。如果基本數據繼續表明長期可持續增長，當前的拋售可能是值得考慮的機會。長期跟蹤股票價格表現總是很有趣的。但要更好地了解BioCryst製藥公司，我們需要考慮許多其他因素。例如，承擔風險——BioCryst製藥公司有3個警告標誌（以及1個不能被忽視的標誌），我們認爲您應該知道。
A Different Perspective
不同的觀點
BioCryst Pharmaceuticals shareholders are down 8.4% for the year, but the market itself is up 26%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Longer term investors wouldn't be so upset, since they would have made 11%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand BioCryst Pharmaceuticals better, we need to consider many other factors. Take risks, for example - BioCryst Pharmaceuticals has 3 warning signs (and 1 which can't be ignored) we think you should know about.
BioCryst製藥公司的股東今年虧損了8.4％，但市場本身上漲了26％。即使好股票的股票價格有時也會下跌，但我們要看到企業基本度量指標的改善才會產生興趣。長期投資者不會那麼沮喪，因爲他們在五年內每年都會獲得11％的回報。如果基本數據繼續表明長期可持續增長，當前的拋售可能是值得考慮的機會。長期跟蹤股票價格表現總是很有趣的。但要更好地了解BioCryst製藥公司，我們需要考慮許多其他因素。例如，承擔風險——BioCryst製藥公司有3個警告標誌（以及1個不能被忽視的標誌），我們認爲您應該知道。
BioCryst Pharmaceuticals is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying.
BioCryst製藥公司並不是內部人員正在購買的唯一股票。因此，請查看此免費列表，其中包含內部人員一直在購買的小盤公司和具有吸引力估值的公司。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意，本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者，發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。